Navigating the Growing 3D Bioprinting Market Forecast till 2030

The Global 3D Bioprinting Market is projected to reach USD 3.3 billion by 2027 from USD 1.3 billion in 2022, at a CAGR of 20.8% during the forecast period

3D bioprinting is a revolutionary technology that is revolutionizing the healthcare industry. This technology uses 3D printing technology to create living human or animal cells in a specific pattern and structure. 3D bioprinting is used to create complex biological structures such as organs and tissues for medical applications. It has the potential to revolutionize the way treatments are designed and delivered and could potentially lead to the development of artificial organs for transplantation and other medical interventions.

The Global 3D Bioprinting Market is projected to reach USD 3.3 billion by 2027 from USD 1.3 billion in 2022, at a CAGR of 20.8% during the forecast period. The technological advancements in 3D bioprinters biomaterials, increasing use of 3D bioprinting in the pharmaceutical and cosmetology industries, and rising public and private funding to support bioprinting research activities are mainly driving the growth in this market. However, shortage of skilled professionals and high development and production costs are restraining the growth of this market.

The global 3D bioprinting market is expected to grow at a significant rate in the forecast period of 2020 to 2027. The rising prevalence of chronic diseases, technological advancements, and increasing government support are the major drivers for the growth of the market. Additionally, the increasing investment in research and development activities, and the increasing number of collaborations among the market players are expected to propel the market growth.

Request for assumptions how numbers were triangulated.

https://www.marketsandmarkets.com/requestsampleNew.asp?id=170201787

Growth Drivers: Increasing use of 3D bioprinting in pharmaceutical and cosmetology industries

Several pharmaceutical companies are increasingly adopting 3D bioprinting products and technologies in the drug discovery and development process. The 3D bioprinting method enables pharmaceutical companies to test drugs more safely and at a lower cost as compared to the traditional drug testing method. The traditional drug discovery process takes around three-to-six years to complete, while the 3D bioprinting process enables pharmaceutical companies to test a drug within a few hours. The use of 3D bioprinted tissues also enables Ramp;D teams to test new drugs in the early stages and during preclinical trials. Advantages offered by 3D bioprinting include reduced use of animals for dug testing, enhanced productivity and shortened drug discovery process.

OPPORTUNITIES: Rising demand for organ transplants

3D printing is gaining increasing importance in the healthcare industry due to the potential for developing complex solid organs like the heart, kidneys, and lungs for transplantation. As opposed to the conventional replacement of failing or damaged organs-which carries a risk of rejection by the host body-3D-printed organs are unlikely to pose any hazards, as they make use of cells taken from the patient’s body.

The global 3D bioprinting market is highly fragmented, with many players operating in the market. The top two players in the market-BICO Group AB (US) and 3D Systems, Inc. (US) (Allevi Inc.)-accounted for a share of ~10-15%. There are many small, medium, and emerging companies in this market, accounting for around 85-90% of the market. Therefore, the intensity of competitive rivalry in the 3D bioprinting market is low. 

Download an Illustrative Overview:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=170201787

Growth Drivers

  • Increasing use of 3D bioprinting in pharmaceutical and cosmetology industries
  • Developments in 3D bioprinting for tissue and organ regeneration applications
  • Rising public and private funding to support bioprinting research activities
  • Technological advancements in 3D bioprinting industry

Growth Opportunities

  • Rising demand for organ transplants

Geographically, the global 3D bioprinting market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East Africa. North America is expected to dominate the global market due to the increasing prevalence of chronic diseases, technological advancements, and increasing government support. Additionally, the presence of major players in the region is expected to boost the market growth.

Recent Developments:

  • In March 2022, BICO Group AB (US) launched the BIO CELLX, which is a novel system that automates 3D cell cultureworkflows by leveraging prevalidated protocols.
  • In June 2021, 3D Systems, Inc. (US) and CollPlant Biotechnologies Ltd. (Israel) signed a co-development agreement for a 3D-bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant.

Content Source:

https://www.marketsandmarkets.com/Market-Reports/3d-bioprinting-market-170201787.html

https://www.prnewswire.com/news-releases/3d-bioprinting-market-worth-3-3-billion-by-2027--exclusive-report-by-marketsandmarkets-301584609.html


Prachee001

574 Blog posts

Comments